TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$225 Million

Biohaven Ltd.

Follow-on Offering

Active Bookrunner, October 2023

Biohaven Ltd.

Biohaven is a clinical-stage biopharmaceutical company committed to transforming the treatment paradigm for people living with debilitating neurological and neuropsychiatric diseases. The Company is advancing its broad and diverse pipeline across early and late-stage development, including three Phase 3 clinical programs. Lead Asset, BHV-7000, a next-gen Kv7.2/7.3 channel activator, is being developed for the adjunctive treatment of focal epilepsy.